

(PB3998) TREOSULFAN-BASED REDUCED-INTENSITY CONDITIONING FOR ALLOGENEIC HCT IN OLDER AND HIGHLY COMORBID PATIENTS: A SINGLE-CENTER REAL-WORLD COHORT

Topic: 23. Stem cell transplantation - Clinical

MacArena Castillo Godoy^{*1}, Maria Orviz Garcia¹, Ana María Pilar González Rodríguez¹, Ana Julia Gonzalez Huerta¹, Soledad González Muñoz¹, Pilar Palomo¹, Joud Zanabili¹

¹*Hospital Universitario Central de Asturias, Oviedo, Spain;*

Background

Allogeneic hematopoietic stem cell transplantation (alloHCT) is the only potential curative treatment for patients. Nevertheless, older or comorbid alloHCT recipients are at greater risk for several alloHCT-related complications. Treosulfan has emerged as an optimal part of prior HCT conditioning regimens in this patient population.

Aims

Analyze the outcome of patients who underwent alloHCT with treosulfan-based conditioning for myeloid neoplasms.

Methods

We retrospectively analyzed the outcome of adult pts with myeloid neoplasms who underwent alloHCT with treosulfan-based conditioning from a matched or mismatched donor from June 2023 to December 2025 at the Hospital Universitario Central Asturias. The conditioning consisted of a combination of treosulfan 10g/m² /day on days -6 to -4, fludarabine, 30mg/m² /day on days -6 to -2. Survival outcomes were estimated using Kaplan–Meier methods.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

Results

We included 34 patients, 23 (67.6%) were male with a median age of 68 years (range 48-75). Median follow-up was 573 days. Patient and transplant characteristics are listed in Table 1. Stem cell source was peripheral blood in all cases. The patients' baseline diseases were: acute myeloblastic leukemia (41.2%), myelodysplastic syndrome (38.2%) and other myeloid neoplasms (20.6%). Nine from 14 AML patients (64.3%) had assigned as adverse genetic risk group at the 2022 ELN. Among 13 patients with MDS, 6 patients had scored as intermediate-1 IPSS-R, 6 as intermediate-2 and 1 as high-risk group.

The median time to neutrophil engraftment was 17.5 days (range 16–20.8), 18 days for platelet engraftment (range 14–22), significantly slower after haplo-HSCT (26 vs. 15 days; $p=0.0001$). Considering early toxicity, 11 of 34 patients (32.4%) suffered from mucositis (grade ≥ 2 in 14.7%) and 3 patients from SOS (8.8%). Eight of 34 patients (23.5%) developed acute GVHD (grade II–III, no one grade IV), and 23.5% (8 patients) had chronic GVHD of any grade (only 5 moderate-severe).

At day +100, 24 patients had achieved CR (70.6%), from whom 21 (87.5%) got MRD negative. Relapse occurred in 8 patients (23.5%) with a median of 77 days. Median OS was not reached and median PFS was 2.4 years; the 2-year OS was 67% and RFS was 59.9%. NRM was 14.7%. Main causes of death were disease relapse (4 patients), infections (1 patients), GVHD (2 patients) and other causes in remainder.

Fitness / Comorbidity	
HCT-CI > 2, n (%)	25 (73.5)
ECOG ≤ 2 , n (%)	33 (97.1)
Diagnosis	
AML, n (%)	14 (41.2)
MDS, n (%)	13 (38.2)
Other myeloid neoplasms, n (%)	7 (20.6)
Donor type	
MRD, n (%)	10 (29.4)
MUD 10/10, n (%)	14 (41.2)
MMUD 9/10, n (%)	2 (5.9)
Haploidentical, n (%)	8 (23.5)
GVHD prophylaxis	
ATG + MTX + CNI, n (%)	23 (67.6)
PTCy + MMF + CNI, n (%)	9 (26.5)
Other, n (%)	2 (5.9)
CMV prophylaxis	
Letermovir, n (%)	14 (41.2)
Pre-transplant comorbidities and health conditions, %	
Pulmonary comorbidity, n (%)	9 (26.5)
Hepatic comorbidity, n (%)	4 (11.8)
Neurologic comorbidity, n (%)	1 (2.9)
Age > 60 with comorbidity, n (%)	10 (29.4)
Age > 70, n (%)	7 (20.6)
Second transplant, n (%)	3 (8.8)
Additional secondary reason present, n (%)	13 (38.2)

Copyright Information: (Online) ISSN: 2572-9241


©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

Summary/Conclusion

Our retrospective analysis suggests that a treosulfan-based RIC in an elderly and population with comorbidities is feasible, with an excellent engraftment rate and a limited early toxicity, GVHD and NRM. These data outline the patient profiles and practical drivers that most often led to treosulfan use in routine transplant care.



Copyright Information: (Online) ISSN: 2572-9241
©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.
Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.